Member Site Core Abstract NRG Oncology (NRG) has established a large and diverse membership that includes 220 Tier 1 (Main Members) and 1188 Tier 2 enrolling sites. NRG Main Members and affiliates are located in all 50 states, Washington, DC, and Puerto Rico. There are 16 Canadian Main Members and 12 Non-North American Main Members located in 8 countries. NRG Oncology has the largest membership base of the groups in the NCI National Clinical Trials Network (NCTN), and NRG members also contribute the highest percentage of patients to the NCTN. For the period of March 1, 2014, through August 31, 2017, NRG trial accrual plus accrual to other NCTN group trials credited to NRG by its members represents approximately a third of the total NCTN accrual for that grant period. Of the 9,000 American patients enrolled on NRG trials during this time period, 12.7% self-identified as of African descent, 8.0% as Hispanic or Latino, and 1.3% as Native Hawaiian, other Pacific Islander, Native American, or Alaska native.. NRG has developed an audit program which is in compliance with the guidelines established by the NCI's Clinical Trials Monitoring Branch (CTMB). In addition, NRG carefully evaluates protocol accrual and data quality, a practice which enables the group to identify and intervene when underperforming centers are identified. NRG has developed a variety of accrual enhancement efforts including: the NRG Protocol Support Committee that reviews all proposed protocols relative to nursing and non-nursing matters; the NRG Health Disparities Committee whose primary aim is to increase enrollment of underrepresented populations to NRG trials; the Communications Committee which provides updates to the NRG members and general public promoting NRG activities and trials; the Center for Innovation in Radiation Oncology (CIRO) which assists NRG members with radiotherapy and imaging quality assurance process, including site qualification, credentialing and case reviews; and a Toll-Free 800 Line available for NRG members to obtain answers to protocol related questions. NRG cancer disease site committees have developed successful programs for patients with rare tumors and trials that provide an opportunity to enroll adolescent and young adult patients.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Nrg Oncology Foundation, Inc.
United States
Zip Code
Konski, Andre; Bhargavan, Mytheryi; Owen, Jean et al. (2018) An Economic Analysis of Radiation Therapy Oncology Group 94-10: Cost-Efficacy of Concurrent vs. Sequential Chemoradiotherapy. J Radiat Oncol 7:195-201
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121
Aghajanian, Carol; Filiaci, Virginia; Dizon, Don S et al. (2018) A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol 150:274-281
Boxerman, Jerrold L; Zhang, Zheng; Safriel, Yair et al. (2018) Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686. Neuro Oncol 20:1400-1410
Monk, Bradley J; Kauderer, James T; Moxley, Katherine M et al. (2018) A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol 151:422-427
Hamilton, C A; Miller, A; Casablanca, Y et al. (2018) Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study. Gynecol Oncol 148:275-280
Hensley, Martee L; Enserro, Danielle; Hatcher, Helen et al. (2018) Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol :JCO1800454
Wang, Liewei; Ingle, James; Weinshilboum, Richard (2018) Pharmacogenomic Discovery to Function and Mechanism: Breast Cancer as a Case Study. Clin Pharmacol Ther 103:243-252
Shi, Wenyin; Scannell Bryan, Molly; Gilbert, Mark R et al. (2018) Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. Int J Radiat Oncol Biol Phys 100:38-44
Younge, Kelly C; Marsh, Robin B; Owen, Dawn et al. (2018) Improving Quality and Consistency in NRG Oncology Radiation Therapy Oncology Group 0631 for Spine Radiosurgery via Knowledge-Based Planning. Int J Radiat Oncol Biol Phys 100:1067-1074

Showing the most recent 10 out of 357 publications